18 th March 2016, Amsterdam, Netherlands. Real-world studies with nearly 600 inflammatory bowel disease (IBD) patients in eight countries show comparable efficacy and safety following a switch to ...

Celltrion announced on the 19th that it has received additional approval from Health Canada for the autoimmune disease treatment Remsima SC (generic name infliximab) for the indication of inflammatory ...

Rheumatoid arthritis, inflammatory bowel disease can now be treated at home by patient Celltrion Pharm said Monday that it is rolling out Remsima SC in Korea for at-home treatment of rheumatoid ...

Celltrion Healthcare has today announced the launch of Remsima™ (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a Korean company to achieve blockbuster status, the biotech company said Wednesday ...

Celltrion said on the 2nd that it will showcase its autoimmune disease treatments at the 2025 United European Gastroenterology Week (UEGW), Europe's largest gastroenterology conference, to be held in ...

Celltrion announced on the 28th that the market share of its autoimmune disease treatment ‘Remsima SC (ingredient name infliximab)’ has more than quintupled in the European market within four years of ...

European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg ...

As a result of the CHMP opinion, if agreed by European Commission (EC), Remsima ® SC 120 mg can be used without IV infusion both for new and existing RA patients. The recommended posology for newly ...

Celltrion received a positive opinion for marketing its subcutaneous-type Remsima from the Committee for Medicinal Products for Human Use of the European Medicines Agency, the company said Monday. A ...

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare has today announced the launch of Remsima™ (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, ...